It was reported on Wednesday that United States-based Additive Orthopaedics LLC has received approval from the United States Food and Drug Administration (FDA) for the Patient Specific Talus Spacer 3D-printed talus (ankle bone) implant for humanitarian use.
The product is a 3D printed implant that can be used in talus replacement surgery. The talus spacer is made individually for each patient, modelled from computed tomography imaging, and is fitted to a patient's specific anatomy. The Patient Specific Talus Spacer is claimed to be the first in the world and first-of-its-kind implant to replace the talus, the bone in the ankle joint that connects the leg and the foot, for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes the death of bone tissue stemming from a lack of blood supply to the area.
The US FDA has reviewed data for the Patient Specific Talus Spacer via the humanitarian device exemption process.
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117